Malignant pleural mesothelioma (MPM) and NF2-mutant tumors represent a molecularly distinct oncological class in which dysregulation of the Hippo–YAP/TAZ–TEAD signaling axis is a defining event. As documented by Nagoya University researchers: "Nearly 75% of MM cases have inactivating mutations in the NF2 gene or in downstream signaling molecules of the Hippo signaling cascade" — making this arguably the most therapeutically actionable molecular axis in MM.

The NF2 gene product, merlin, functions as an upstream activator of the Hippo kinase cascade (MST1/2 → LATS1/2 → phospho-YAP1/TAZ). Its loss leads to constitutive nuclear accumulation of YAP1 and TAZ, which then bind TEAD1–4 transcription factors to drive pro-proliferative and anti-apoptotic gene programs including CTGF (connective tissue growth factor). NF2 mutations occur in approximately 40% of MM cases, with broader Hippo pathway defects identified in up to 50% of tumors in two independent integrated genomics studies from Cambridge and Bern.

Co-occurring loss-of-function alterations in BAP1, CDKN2A/ARF, and TP53 serve as cooperating drivers. Mouse models combining triple disruption of Bap1, Nf2, and Cdkn2ab produce highly aggressive MM with fidelity to human histology and gene expression profiles. Convergent signaling from the TGF-β pathway through YAP1–TEAD4–Smad3–p300 complexes on the CTGF promoter has also been characterized as a mechanism of pathway crosstalk in MM. Explore the full target landscape on the PatSnap Analytics platform.

Bern University Hospital data further establish that NF2 loss-of-function and elevated phospho-YAP are not always co-occurring in MPM, raising the possibility that NF2 contributes via Hippo-independent mechanisms in a subset of tumors — a critical patient stratification insight for clinical development. The National Cancer Institute recognizes mesothelioma as a rare cancer with high unmet need and limited approved targeted therapies.

Retrieved results contain limited direct clinical evidence for TEAD or YAP1-targeted therapies specifically, reflecting the early stage of this inhibitor class. The University of Melbourne explicitly states that "several small-molecule inhibitors of YAP and TEADs have been reported, with some now entering clinical trials for different cancers" — but no trial identifiers or patient data are present in the retrieved text.

The Sanofi paper on YAP1 tumor maintenance in MM supports the rationale for YAP1-targeted therapy but remains an in vivo preclinical study. A 2021 Royal Brompton/Cambridge integrated genomics paper identifies Hippo pathway defects in 50% of MPM tumors and confirms "micromolar responses" to pathway-relevant inhibitors in primary MPM cells — representing an IND-enabling translational signal rather than clinical data.

Verteporfin, used as a YAP/TEAD functional inhibitor in multiple preclinical studies, is an FDA-approved photosensitizer. Its repurposing for systemic Hippo pathway inhibition remains preclinical only based on retrieved evidence. No Phase I/II trial data for TEAD palmitoylation inhibitors in mesothelioma or NF2-mutant tumors are present in retrieved results. The European Patent Office records increasing TEAD-directed patent filings consistent with the emerging clinical translation timeline. For life sciences pipeline intelligence, PatSnap's life sciences platform provides comprehensive clinical-stage tracking.

The overall clinical translation signal in this dataset is at the late preclinical / IND-enabling stage for the most advanced TEAD-targeted small molecules. The mesothelioma preclinical model ecosystem — particularly the Netherlands Cancer Institute's triple-deletion mouse model and primary patient-derived cell lines from Bern and Cambridge — provides the infrastructure needed for IND-enabling studies.